Research study · EULAR Rheumatology Open · 2026
Evaluation of the use of different forms of medical cannabis in the treatment of fibromyalgia: a systematic review
Verified on PubMed Oxford CEBM Level 1A: Systematic Review & Meta-Analysis
A 2026 systematic review in EULAR Rheumatology Open tested medical cannabis in fibromyalgia. The results were mixed and not strong enough to say these medicines reliably help. This review does not show that cannabis-based medicines work for fibromyalgia, and it does not show they fail either.
In plain language
Study overview
Researchers reviewed the best available medical studies that tested cannabis-based medicines in people with a long-lasting condition that causes widespread body pain, poor sleep and tiredness. They looked at a few different versions of these medicines and compared them with dummy pills or standard painkillers.
Findings
The results were mixed and not strong enough to say these medicines reliably help. Some studies showed small improvements in sleep or how much the condition affected daily life, while others found no clear benefit for pain.
Explore Dr. Caplan's interactive tool detailing cytochrome P450 pathways, clinical titration intervals, and physician surveillance rules.
The deeper readScientific analysis
Objectives: To systematically review, based on randomised controlled trials (RCTs), some forms of medical cannabis (nabilone, tetrahydrocannabinol-rich oil, and Bediol) in the treatment of fibromyalgia syndrome (FMS). Methods: PRISMA-guided systematic review; databases Medline/PubMed, Embase, CENTRAL and Scopus; inclusion of RCTs in adults with fibromyalgia by ACR criteria comparing medical cannabis with placebo or current therapy. Results: Only 4 articles were eligible. From them, it was not possible to infer the real impact after the use of 3 forms of medical cannabis (alone or associated with another therapy) on disease, pain, or insomnia. Conclusions: It is not possible to conclude whether different forms of medical cannabis are an effective and safe therapeutic option for the treatment of FMS symptoms, with tolerable adverse effects. This prescription should be made individually for each patient.
The paper
Citation
Duarte GO, Feitosa MHR, Bringel FA, Prado SMB Evaluation of the use of different forms of medical cannabis in the treatment of fibromyalgia: a systematic review. EULAR Rheumatology Open (2026). PubMed 42370077 · DOI
Read the abstract as published
OBJECTIVES: To systematically review, based on randomised controlled trials (RCTs), some forms of medical cannabis (nabilone, tetrahydrocannabinol-rich oil, and Bediol) in the treatment of fibromyalgia syndrome (FMS).
METHODS: According to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses diagram for systematic reviews (SRs), the PICO strategy was delimited, and articles with entry terms (medical subject headings) referring to 'medicinal cannabis' and 'fibromyalgia' were searched in the following databases: Medline, via PubMed; Embase; Central, via Cochrane; and Scopus, via Elsevier. The inclusion criteria were as follows: (1) patients of any age, gender, or ethnicity diagnosed with fibromyalgia according to the criteria of the American College of Rheumatology (ACR 1990, 2010, or 2016); (2) undergoing treatment with some type of medical cannabis, regardless of the route of administration, dosage, or duration of treatment (except single dose), compared with current therapy or placebo; and (3) RCTs, blinded or not, published in any language, without time restriction.
RESULTS: Only 4 articles were eligible for the production of this SR. From them, it was not possible to infer the real impact after the use of 3 forms of medical cannabis (alone or associated with another therapy) on disease, pain, or insomnia.
CONCLUSIONS: It is not possible to conclude whether different forms of medical cannabis are an effective and safe therapeutic option for the treatment of FMS symptoms, with tolerable adverse effects. This prescription should be made individually for each patient.
Abstract text as indexed by PubMed for this identifier.
Limitations the authors noted
Very small number of eligible trials and small sample sizes. Heterogeneous cannabis formulations, doses, routes and durations. Short follow-up periods. Risk of bias in included trials (one high, one with concerns). SD values estimated from baseline or P values for some trials. Limited GRADE certainty (very low) for pooled outcomes.
In practice
Why this matters
This review does not show that cannabis-based medicines work for fibromyalgia, and it does not show they fail either. It points to the need for larger and longer studies that test one specific form at a time before firm conclusions can be drawn. Readers should treat any use as an individual decision with careful monitoring, since the side effects were generally mild but still present.
Frequently asked questions
Clinical Questions & Answers
What did this study show regarding cannabinoids for Pain?
The results were mixed and not strong enough to say these medicines reliably help. Some studies showed small improvements in sleep or how much the condition affected daily life, while others found no clear benefit for pain.
How does Dr. Benjamin Caplan interpret these results for clinical practice?
This review does not show that cannabis-based medicines work for fibromyalgia, and it does not show they fail either. It points to the need for larger and longer studies that test one specific form at a time before firm conclusions can be drawn. Readers should treat any use as an individual decision with careful monitoring, since the side effects were generally mild but still present.
What study limitations or clinical safeguards should patients keep in mind?
Very small number of eligible trials and small sample sizes. Heterogeneous cannabis formulations, doses, routes and durations. Short follow-up periods.
Browse related research
Condition: Fibromyalgia Condition: Insomnia Condition: Pain Topic: Cannabis Topic: Medical cannabis Topic: THC
Related on CED Clinic
Back to Daily Research and Patient Questions
Reviewed by Dr. Caplan on October 14, 2026.
This page is general education about a published study. It is not medical advice and does not create a doctor-patient relationship. For care specific to you, book a consultation.
